Multi-omics technology reveals the changes in gut microbiota to stimulate aromatic amino acid metabolism in children with allergic rhinitis and constipation

多组学技术揭示肠道菌群的变化如何刺激过敏性鼻炎和便秘患儿的芳香族氨基酸代谢

阅读:3

Abstract

BACKGROUND: Comorbid allergic rhinitis and constipation (ARFC) in children are associated with gut microbiota (GM) dysbiosis and metabolic perturbations; however, the underlying mechanistic interplay remains unclear. OBJECTIVE: This multi-omics study aimed to characterize GM and fecal metabolomic signatures in preschool ARFC children and elucidate microbial-metabolite interactions driving dual symptomatology. METHODS: Fecal samples from 16 ARFC and 15 healthy control (HC) children underwent high-throughput absolute quantification 16S rRNA sequencing and untargeted metabolomics. Differential taxa and metabolites were identified via LEfSe and OPLS-DA (VIP > 1, false discovery rate (FDR) q < 0.05). Microbial-metabolite networks were reconstructed using genome-scale metabolic modeling and KEGG pathway analysis. RESULTS: The ARFC group exhibited distinct β-diversity (P = 0.031), marked by elevated Hungatella, Tyzzerella, and Bifidobacterium longum (P < 0.05). Metabolomics revealed upregulated aromatic amino acids (AAAs), neurotransmitters, and bile acids (FDR q < 0.05), with enrichment in tryptophan/tyrosine pathways (P < 0.01). Bioinformatic modeling linked Hungatella to tryptophan hydroxylase (EC:1.14.16.4), driving serotonin synthesis, and Tyzzerella to indoleamine 2,3-dioxygenase (EC:1.13.11.52), promoting kynurenine production. Bifidobacterium longum correlated with phenylalanine hydroxylase (EC:1.14.16.1), enhancing phenylalanine derivatives. A combined GM-metabolite diagnostic model demonstrated robust accuracy (AUC = 0.8). CONCLUSION: GM dysbiosis in ARFC children activates AAA metabolism, generating neuroactive and pro-inflammatory metabolites that may exacerbate allergic and gastrointestinal symptoms. These findings highlight microbial-metabolite axes as therapeutic targets. Study limitations include cohort size and lack of disease-specific controls, necessitating validation in expanded cohorts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。